161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Market cap: $3.3B (2/08/2026)
Price: $20.84
Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Investor Presentation
Announce $275 Million Royalty Funding Agreement
Earnings Release
Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
Reports Second Quarter 2025 Financial Results and Business Highlights
Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence